FLT3 and cancer: Gilteritinib, a second-generation type I inhibitor, was not available in the Genomics of Drug Sensitivity in Cancer database, but had a reported IC50 value of approximately 1.5-12 nM for cells with various FLT3 mutations and wild-type FLT3 [38].